210 related articles for article (PubMed ID: 36329634)
1. Long-term variations and potency of neutralizing antibodies against Omicron subvariants after CoronaVac-inactivated booster: A 7-month follow-up study.
Li X; Yin Y; Cui Q; Huang W; Zou Q; Shen T
J Med Virol; 2023 Jan; 95(1):e28279. PubMed ID: 36329634
[TBL] [Abstract][Full Text] [Related]
2. Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants.
Wang XJ; Yao L; Zhang HY; Zhu KL; Zhao J; Zhan BD; Li YK; He XJ; Huang C; Wang ZY; Jiang MD; Yang P; Yang Y; Wang GL; Wang SQ; Dai EH; Gao HX; Ma MJ
Genome Med; 2022 Dec; 14(1):146. PubMed ID: 36581867
[TBL] [Abstract][Full Text] [Related]
3. Second booster dose improves antibody neutralization against BA.1, BA.5 and BQ.1.1 in individuals previously immunized with CoronaVac plus BNT162B2 booster protocol.
Campos GRF; Almeida NBF; Filgueiras PS; Corsini CA; Gomes SVC; de Miranda DAP; de Assis JV; Silva TBS; Alves PA; Fernandes GDR; de Oliveira JG; Rahal P; Grenfell RFQ; Nogueira ML
Front Cell Infect Microbiol; 2024; 14():1371695. PubMed ID: 38638823
[TBL] [Abstract][Full Text] [Related]
4. Neutralizing activity of a third dose of CoronaVac against Omicron subvariants within a 20-month follow-up study.
Cao C; Guo Q; Dai Y; Jiang J; Liu M; Ji T; Zhou P; Gong F
Hum Vaccin Immunother; 2023 Aug; 19(2):2242217. PubMed ID: 37529941
[TBL] [Abstract][Full Text] [Related]
5. Durability of neutralization against Omicron subvariants after vaccination and breakthrough infection.
Zhu KL; Jiang XL; Zhan BD; Wang XJ; Xia X; Cao GP; Sun WK; Huang PX; Zhang JZ; Gao YL; Dai EH; Gao HX; Ma MJ
Cell Rep; 2023 Feb; 42(2):112075. PubMed ID: 36774551
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal data on humoral response and neutralizing antibodies against SARS-CoV-2 Omicron BA.1 and subvariants BA.4/5 and BQ.1.1 after COVID-19 vaccination in cancer patients.
Overheu O; Lendowski S; Quast DR; Kühn D; Vidal Blanco E; Kraeft AL; Steinmann E; Kourti E; Lugnier C; Steinmann J; Reinacher-Schick A; Pfaender S
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10633-10644. PubMed ID: 37300723
[TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2 vaccination of convalescents boosts neutralization capacity against Omicron subvariants BA.1, BA.2 and BA.5 and can be predicted by anti-S antibody concentrations in serological assays.
Seidel A; Hoffmann S; Jahrsdörfer B; Körper S; Ludwig C; Vieweg C; Albers D; von Maltitz P; Müller R; Lotfi R; Wuchter P; Klüter H; Kirchhoff F; Schmidt M; Münch J; Schrezenmeier H
Front Immunol; 2023; 14():1170759. PubMed ID: 37180152
[TBL] [Abstract][Full Text] [Related]
8. Neutralizing antibody response to XBB.1.5, BA.2.86, FL.1.5.1, and JN.1 six months after the BNT162b2 bivalent booster.
Favresse J; Gillot C; Cabo J; David C; Dogné JM; Douxfils J
Int J Infect Dis; 2024 Jun; 143():107028. PubMed ID: 38583825
[TBL] [Abstract][Full Text] [Related]
9. COVID-19 booster vaccination during pregnancy enhances maternal binding and neutralizing antibody responses and transplacental antibody transfer to the newborn.
Munoz FM; Posavad CM; Richardson BA; Badell ML; Bunge KE; Mulligan MJ; Parameswaran L; Kelly CW; Olson-Chen C; Novak RM; Brady RC; Pasetti MF; Defranco EA; Gerber JS; Shriver MC; Suthar MS; Coler RN; Berube BJ; Kim SH; Piper JM; Miller AM; Cardemil CV; Neuzil KM; Beigi RH;
Vaccine; 2023 Aug; 41(36):5296-5303. PubMed ID: 37451878
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the replication and neutralization of different SARS-CoV-2 Omicron subvariants in vitro.
Zhang Y; Lv Q; Qi F; Li F; Deng R; Liang X; Liu M; Yan Y; Bao L
Animal Model Exp Med; 2023 Feb; 6(1):51-56. PubMed ID: 36808904
[TBL] [Abstract][Full Text] [Related]
11. Effects of a booster dose of BNT162b2 on spike-binding antibodies to SARS-CoV-2 Omicron BA.2, BA.3, BA.4 and BA.5 subvariants in infection-naïve and previously-infected individuals.
Kuzel TG; Fu J; Anderson M; Stec M; Boler M; Behun D; Gosha A; Cloherty G; Landay A; Moy J
Vaccine; 2023 Jan; 41(4):879-882. PubMed ID: 36572601
[TBL] [Abstract][Full Text] [Related]
12. Durability of the Neutralizing Antibody Response to mRNA Booster Vaccination Against SARS-CoV-2 BA.2.12.1 and BA.4/5 Variants.
Qu P; Faraone JN; Evans JP; Zheng YM; Carlin C; Lozanski G; Saif LJ; Oltz EM; Gumina RJ; Liu SL
bioRxiv; 2022 Jul; ():. PubMed ID: 35898337
[TBL] [Abstract][Full Text] [Related]
13. Effect of vaccine booster, vaccine type, and hybrid immunity on humoral and cellular immunity against SARS-CoV-2 ancestral strain and Omicron variant sublineages BA.2 and BA.5 among older adults with comorbidities: a cross sectional study.
Fong CH; Zhang X; Chen LL; Poon RW; Chan BP; Zhao Y; Wong CK; Chan KH; Yuen KY; Hung IF; Yuen JKY; To KK
EBioMedicine; 2023 Feb; 88():104446. PubMed ID: 36706582
[TBL] [Abstract][Full Text] [Related]
14. Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination.
Bellusci L; Grubbs G; Zahra FT; Forgacs D; Golding H; Ross TM; Khurana S
Nat Commun; 2022 Aug; 13(1):4617. PubMed ID: 35941152
[TBL] [Abstract][Full Text] [Related]
15. Effects of boosted mRNA and adenoviral-vectored vaccines on immune responses to omicron BA.1 and BA.2 following the heterologous CoronaVac/AZD1222 vaccination.
Suntronwong N; Kanokudom S; Auphimai C; Assawakosri S; Thongmee T; Vichaiwattana P; Duangchinda T; Chantima W; Pakchotanon P; Chansaenroj J; Puenpa J; Nilyanimit P; Srimuan D; Thatsanatorn T; Sudhinaraset N; Wanlapakorn N; Mongkolsapaya J; Poovorawan Y
J Med Virol; 2022 Dec; 94(12):5713-5722. PubMed ID: 35924475
[TBL] [Abstract][Full Text] [Related]
16. Increased antibody titers but induced T cell AICD and apoptosis response in COVID-19 convalescents by inactivated vaccine booster.
Zhao J; Zhang H; Jiang L; Cheng F; Li W; Wang Z; Liu H; Li S; Jiang Y; Li M; Li Y; Liu S; Fang M; Zhou X; Ye X; Zhao S; Zheng Y; Meng S
Microbiol Spectr; 2024 Mar; 12(3):e0243523. PubMed ID: 38319108
[TBL] [Abstract][Full Text] [Related]
17. Low Neutralizing Activities to the Omicron Subvariants BN.1 and XBB.1.5 of Sera From the Individuals Vaccinated With a BA.4/5-Containing Bivalent mRNA Vaccine.
Nham E; Kim J; Lee J; Park H; Kim J; Lee S; Choi J; Kim KT; Yoon JG; Hwang SY; Song JY; Cheong HJ; Kim WJ; Park MS; Noh JY
Immune Netw; 2023 Dec; 23(6):e43. PubMed ID: 38188597
[TBL] [Abstract][Full Text] [Related]
18. An omicron-based vaccine booster elicits potent neutralizing antibodies against emerging SARS-CoV-2 variants in adults.
Li T; Luo D; Ning N; Wang X; Zhang L; Yang X; Li D; Sun Y; Yu W; Wei W; Wang H
Emerg Microbes Infect; 2023 Dec; 12(1):2207670. PubMed ID: 37272331
[TBL] [Abstract][Full Text] [Related]
19. Dynamic Humoral Immune Response to Primary and Booster Inactivated SARS-CoV-2 Vaccination in Patients with Cirrhosis.
Zhu Q; Wang L; Hu X; Zhang Y; Huang T; He T; Chen Z; Zhang G; Peng M; Chen M; Cai D; Shi X; Ren H
J Clin Transl Hepatol; 2023 Dec; 11(7):1476-1484. PubMed ID: 38161494
[TBL] [Abstract][Full Text] [Related]
20. Plaque-neutralizing antibody to BA.2.12.1, BA.4 and BA.5 in individuals with three doses of BioNTech or CoronaVac vaccines, natural infection and breakthrough infection.
Cheng SS; Mok CK; Li JK; Ng SS; Lam BH; Jeevan T; Kandeil A; Pekosz A; Chan KC; Tsang LC; Ko FW; Chen C; Yiu K; Luk LL; Chan KK; Webby RJ; Poon LL; Hui DS; Peiris M
J Clin Virol; 2022 Nov; 156():105273. PubMed ID: 36081282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]